Skip to main content
Erschienen in: Medical Oncology 8/2021

28.07.2021 | COVID-19 | Review Article Zur Zeit gratis

Vaccination of cancer patients against COVID-19: towards the end of a dilemma

verfasst von: Avik Mandal, Pritanjali Singh, Arghadip Samaddar, Dharmendra Singh, Manika Verma, Amrita Rakesh, Rakesh Ranjan

Erschienen in: Medical Oncology | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

With the emergence of second wave of COVID-19 infection globally, particularly in India in March–April 2021, protection by massive vaccination drive has become the need of the hour. Vaccines have been proved to reduce the risk of developing severe illness and are emerging as vital tools in the battle against COVID-19. As per the GLOBOCAN database, nearly 19.3 million new cancer cases have been reported in 2020 globally, which posed a significant challenge to health care providers to protect such large number of ‘vulnerable’ patients from COVID-19. Nevertheless, a considerable degree of doubt, hesitancy and misconceptions are noted regarding the administration of vaccines particularly during active immuno-suppressant treatment. This review article highlights the added vulnerability of cancer patients to the COVID-19 infection and has explored the immunological challenges associated with malignancy, anticancer treatment and COVID-19 vaccination.
Anhänge
Nur mit Berechtigung zugänglich
Fußnoten
1
GLOBOCAN 2020: New Global Cancer Data | UICC. Available from: https://​www.​uicc.​org/​news/​globocan-2020-new-global-cancer-data. (Accessed May 15, 2021).
 
2
COVID-19 Vaccine Communication Strategy: 2 Gaj Ki Doori. www.​mohfw.​gov.​in. (Accessed May 4, 2021).
 
3
COVID-19 and Cancer Consortium Registry—Full Text View—ClinicalTrials.gov. https://​clinicaltrials.​gov/​ct2/​show/​NCT04354701. (Accessed May 6, 2021).
 
4
Centers for Disease Control and Prevention (CDC). Summary Document for Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States—FactSheet. Available from: https://​www.​cdc.​gov/​vaccines/​covid-
19/downloads/summary-interim-clinical-considerations.pdf.
 
5
Preliminary recommendations of the NCCN COVID-19 Vaccination Advisory.
Committee [press release]. 2021.
 
6
SITC Statement on SARS-CoV-2 Vaccination and Cancer Immunotherapy. Available.
d_cancer_immunotherapy/prweb17633616.htm. (Accessed May 17, 2021).
 
7
Coronavirus Vaccines and People with Cancer—National Cancer Institute.
vaccine. (Accessed May 13, 2021).
 
8
Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC. Available.
html. (Accessed May 13, 2021).
 
Literatur
1.
Zurück zum Zitat Giuliani J, Bonetti A. Cancer prevales on COVID-19: to maintain high quality standard concerning diagnosis and oncological care even during a pandemic. J Med Virol. 2021;93:118–9.CrossRef Giuliani J, Bonetti A. Cancer prevales on COVID-19: to maintain high quality standard concerning diagnosis and oncological care even during a pandemic. J Med Virol. 2021;93:118–9.CrossRef
2.
Zurück zum Zitat Kramer DB, Opel DJ, Parasidis E, Mello MM. Choices in a crisis–individual preferences among SARS-CoV-2 vaccines. N Engl J Med. 2021;384:e62.CrossRef Kramer DB, Opel DJ, Parasidis E, Mello MM. Choices in a crisis–individual preferences among SARS-CoV-2 vaccines. N Engl J Med. 2021;384:e62.CrossRef
3.
Zurück zum Zitat Hijano DR, Maron G, Hayden RT. Respiratory viral infections in patients with cancer or undergoing hematopoietic cell transplant. Front Microbiol. 2018;9:3097.CrossRef Hijano DR, Maron G, Hayden RT. Respiratory viral infections in patients with cancer or undergoing hematopoietic cell transplant. Front Microbiol. 2018;9:3097.CrossRef
4.
Zurück zum Zitat Bitterman R, Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev. 2018;2:CD008983.PubMed Bitterman R, Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev. 2018;2:CD008983.PubMed
5.
Zurück zum Zitat Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10:783–91.PubMedPubMedCentral Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10:783–91.PubMedPubMedCentral
6.
Zurück zum Zitat Codacci-Pisanelli G, Giuliani J, Bonetti A. The effect of COVID-19 pandemic on daily oncology clinical practice. Crit Rev Oncol Hematol. 2021;395:103272.CrossRef Codacci-Pisanelli G, Giuliani J, Bonetti A. The effect of COVID-19 pandemic on daily oncology clinical practice. Crit Rev Oncol Hematol. 2021;395:103272.CrossRef
7.
Zurück zum Zitat Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. COVID-19 and cancer consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–18.CrossRef Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. COVID-19 and cancer consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–18.CrossRef
8.
Zurück zum Zitat Lee LY, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395:1919–26.CrossRef Lee LY, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395:1919–26.CrossRef
9.
Zurück zum Zitat Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21:914–22.CrossRef Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21:914–22.CrossRef
10.
Zurück zum Zitat Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8:e185–93.CrossRef Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8:e185–93.CrossRef
11.
Zurück zum Zitat Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–92.CrossRef Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–92.CrossRef
12.
Zurück zum Zitat Luo J, Rizvi H, Egger JV, Preeshagul IR, Wolchok JD, Hellmann MD. Impact of pd-1 blockade on severity of covid-19 in patients with lung cancers. Cancer Discov. 2020;10:1121–8.CrossRef Luo J, Rizvi H, Egger JV, Preeshagul IR, Wolchok JD, Hellmann MD. Impact of pd-1 blockade on severity of covid-19 in patients with lung cancers. Cancer Discov. 2020;10:1121–8.CrossRef
13.
Zurück zum Zitat Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26:1218–23.CrossRef Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26:1218–23.CrossRef
14.
Zurück zum Zitat Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383:1503–16.CrossRef Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383:1503–16.CrossRef
15.
Zurück zum Zitat Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–4.CrossRef Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–4.CrossRef
16.
Zurück zum Zitat Derosa L, Melenotte C, Griscelli F, Gachot B, Marabelle A, Kroemer G, et al. The immuno-oncological challenge of COVID-19. Nat Cancer. 2020;1:946–64.CrossRef Derosa L, Melenotte C, Griscelli F, Gachot B, Marabelle A, Kroemer G, et al. The immuno-oncological challenge of COVID-19. Nat Cancer. 2020;1:946–64.CrossRef
18.
Zurück zum Zitat Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996-1012.e19.CrossRef Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996-1012.e19.CrossRef
19.
Zurück zum Zitat Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;4(370):1227–30.CrossRef Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;4(370):1227–30.CrossRef
20.
Zurück zum Zitat Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52:971-977.e3.CrossRef Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52:971-977.e3.CrossRef
21.
Zurück zum Zitat Solodky ML, Galvez C, Russias B, Detourbet P, N’Guyen-Bonin V, Herr AL, et al. Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19. Ann Oncol. 2020;31:1087–8.CrossRef Solodky ML, Galvez C, Russias B, Detourbet P, N’Guyen-Bonin V, Herr AL, et al. Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19. Ann Oncol. 2020;31:1087–8.CrossRef
22.
Zurück zum Zitat Aydillo T, Gonzalez-Reiche AS, Aslam S, van de Guchte A, Khan Z, Obla A, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020;383:2586–8.CrossRef Aydillo T, Gonzalez-Reiche AS, Aslam S, van de Guchte A, Khan Z, Obla A, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020;383:2586–8.CrossRef
23.
Zurück zum Zitat Fuentes-Prior P. Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection. J Biol Chem. 2021;296:100135.CrossRef Fuentes-Prior P. Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection. J Biol Chem. 2021;296:100135.CrossRef
24.
Zurück zum Zitat Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.e8.CrossRef Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.e8.CrossRef
25.
Zurück zum Zitat Choi SY, Bertram S, Glowacka I, Park YW, Pöhlmann S. Type II transmembrane serine proteases in cancer and viral infections. Trends Mol Med. 2009;15:303–12.CrossRef Choi SY, Bertram S, Glowacka I, Park YW, Pöhlmann S. Type II transmembrane serine proteases in cancer and viral infections. Trends Mol Med. 2009;15:303–12.CrossRef
26.
Zurück zum Zitat Clinckemalie L, Spans L, Dubois V, Laurent M, Helsen C, Joniau S, et al. Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element. Mol Endocrinol. 2013;27:2028–40.CrossRef Clinckemalie L, Spans L, Dubois V, Laurent M, Helsen C, Joniau S, et al. Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element. Mol Endocrinol. 2013;27:2028–40.CrossRef
27.
Zurück zum Zitat Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol. 2020;31:1040–5.CrossRef Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol. 2020;31:1040–5.CrossRef
28.
Zurück zum Zitat Lara PC, Burgos J, Macias D. Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment. Clin Transl Radiat Oncol. 2020;23:27–9.CrossRef Lara PC, Burgos J, Macias D. Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment. Clin Transl Radiat Oncol. 2020;23:27–9.CrossRef
29.
Zurück zum Zitat Calabrese EJ, Kozumbo WJ, Kapoor R, Dhawan G, Jimenez PCL, Giordano J. NRF2 activation putatively mediates clinical benefits of low-dose radiotherapy in COVID-19 pneumonia and acute respiratory distress syndrome (ards): novel mechanistic considerations. Radiother Oncol. 2021;160:125–31.CrossRef Calabrese EJ, Kozumbo WJ, Kapoor R, Dhawan G, Jimenez PCL, Giordano J. NRF2 activation putatively mediates clinical benefits of low-dose radiotherapy in COVID-19 pneumonia and acute respiratory distress syndrome (ards): novel mechanistic considerations. Radiother Oncol. 2021;160:125–31.CrossRef
30.
Zurück zum Zitat Waissengrin B, Agbarya A, Safadi E, Padova H, Wolf I. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol. 2021;22:581–3.CrossRef Waissengrin B, Agbarya A, Safadi E, Padova H, Wolf I. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol. 2021;22:581–3.CrossRef
31.
Zurück zum Zitat Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Barrio DMD, I, Alaguthurai T, , et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;S1470–2045(21):00213–8. Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Barrio DMD, I, Alaguthurai T, , et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;S1470–2045(21):00213–8.
32.
Zurück zum Zitat Ribas A, Sengupta R, Locke T, Zaidi SK, Campbell KM, Carethers JM, et al. AACR COVID-19 and cancer task force. Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited. Cancer Discov. 2021;11:233–6.CrossRef Ribas A, Sengupta R, Locke T, Zaidi SK, Campbell KM, Carethers JM, et al. AACR COVID-19 and cancer task force. Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited. Cancer Discov. 2021;11:233–6.CrossRef
33.
Zurück zum Zitat Garassino MC, Vyas M, de Vries EGE, Kanesvaran R, Giuliani R, Peters S. The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: vaccinate. Monitor Educate Ann Oncol. 2021;32:579–81.CrossRef Garassino MC, Vyas M, de Vries EGE, Kanesvaran R, Giuliani R, Peters S. The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: vaccinate. Monitor Educate Ann Oncol. 2021;32:579–81.CrossRef
34.
Zurück zum Zitat Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021;18:313–9.CrossRef Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021;18:313–9.CrossRef
36.
Zurück zum Zitat Zambelli A, Chiudinelli L, Fotia V, Negrini G, Bosetti T, Callegaro A, et al. Prevalence and clinical impact of SARS-CoV-2 silent carriers among actively treated patients with cancer during the COVID-19 pandemic. Oncologist. 2021;26:341–7.CrossRef Zambelli A, Chiudinelli L, Fotia V, Negrini G, Bosetti T, Callegaro A, et al. Prevalence and clinical impact of SARS-CoV-2 silent carriers among actively treated patients with cancer during the COVID-19 pandemic. Oncologist. 2021;26:341–7.CrossRef
37.
Zurück zum Zitat Assaad S, Avrillon V, Fournier ML, Mastroianni B, Russias B, Swalduz A, et al. High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR. Eur J Cancer. 2020;135:251–9.CrossRef Assaad S, Avrillon V, Fournier ML, Mastroianni B, Russias B, Swalduz A, et al. High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR. Eur J Cancer. 2020;135:251–9.CrossRef
38.
Zurück zum Zitat Moiseev S, Avdeev S, Brovko M, Akulkina L, Fomin V. Cancer in intensive care unit patients with COVID-19. J Infect. 2020;81:e124–5.CrossRef Moiseev S, Avdeev S, Brovko M, Akulkina L, Fomin V. Cancer in intensive care unit patients with COVID-19. J Infect. 2020;81:e124–5.CrossRef
39.
Zurück zum Zitat Ma J, Yin J, Qian Y, Wu Y. Clinical characteristics and prognosis in cancer patients with COVID-19: a single center’s retrospective study. J Infect. 2020;81:318–56.CrossRef Ma J, Yin J, Qian Y, Wu Y. Clinical characteristics and prognosis in cancer patients with COVID-19: a single center’s retrospective study. J Infect. 2020;81:318–56.CrossRef
Metadaten
Titel
Vaccination of cancer patients against COVID-19: towards the end of a dilemma
verfasst von
Avik Mandal
Pritanjali Singh
Arghadip Samaddar
Dharmendra Singh
Manika Verma
Amrita Rakesh
Rakesh Ranjan
Publikationsdatum
28.07.2021
Verlag
Springer US
Schlagwort
COVID-19
Erschienen in
Medical Oncology / Ausgabe 8/2021
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-021-01540-8

Weitere Artikel der Ausgabe 8/2021

Medical Oncology 8/2021 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.